MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
0.4450
+0.0057
+1.30%
After Hours: 0.4203 -0.0247 -5.55% 19:57 03/17 EDT
OPEN
0.4411
PREV CLOSE
0.4393
HIGH
0.4499
LOW
0.4100
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
2.800
52 WEEK LOW
0.1800
MARKET CAP
44.84M
P/E (TTM)
-0.3620
1D
5D
1M
3M
1Y
5Y
1D
FibroGen GAAP EPS of $0.18, revenue of $3.1M
Seeking Alpha · 7h ago
FIBROGEN INC: QTRLY NET INCOME PER SHARE $0.18
Reuters · 7h ago
FIBROGEN INC - CASH RUNWAY EXTENDED INTO 2027 UPON SALE CLOSURE
Reuters · 7h ago
Press Release: FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Dow Jones · 7h ago
Press Release: FibroGen Reports Fourth Quarter -2-
Dow Jones · 7h ago
After-Hours Earnings Report for March 17, 2025 : BLTE, HROW, LPRO, HNRG, QTRX, DMAC, SGMO, HITI, HYPR, FGEN, RFIL, AMPS
NASDAQ · 9h ago
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Barchart · 12h ago
Here are the major earnings after the close today
Seeking Alpha · 13h ago
More
About FGEN
More
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Recently
Symbol
Price
%Change

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.